scholarly journals Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies

Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 253
Author(s):  
Sascha Berlansky ◽  
Matthias Sallinger ◽  
Herwig Grabmayr ◽  
Christina Humer ◽  
Andreas Bernhard ◽  
...  

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). This respiratory illness was declared a pandemic by the world health organization (WHO) in March 2020, just a few weeks after being described for the first time. Since then, global research effort has considerably increased humanity’s knowledge about both viruses and disease. It has also spawned several vaccines that have proven to be key tools in attenuating the spread of the pandemic and severity of COVID-19. However, with vaccine-related skepticism being on the rise, as well as breakthrough infections in the vaccinated population and the threat of a complete immune escape variant, alternative strategies in the fight against SARS-CoV-2 are urgently required. Calcium signals have long been known to play an essential role in infection with diverse viruses and thus constitute a promising avenue for further research on therapeutic strategies. In this review, we introduce the pivotal role of calcium signaling in viral infection cascades. Based on this, we discuss prospective calcium-related treatment targets and strategies for the cure of COVID-19 that exploit viral dependence on calcium signals.

2020 ◽  
Vol 7 (4) ◽  
pp. 17-26
Author(s):  
Jitendra Mehta ◽  

Coronavirus disease 2019 (COVID-19) emerged in December 2019 in Wuhan, the capital of Hubei province, China. While the outbreak in China is almost over, this highly contagious disease is currently spreading across the world with a daily increase in the number of affected countries, confirmed cases, and infection-related deaths. In January, the World Health Organization (WHO) declared that the outbreak of COVID-19 constituted a Public Health Emergency of International Concern (PHEIC). Based on the high levels of global spread and the severity of COVID-19, on 11 March 2020, the Director-General of the WHO declared the COVID-19 outbreak a pandemic. COVID-19 is an acute respiratory disease caused by a newly emerged zoonotic coronavirus. A positive-sense enveloped single-stranded RNA virus, named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has been isolated from a patient with pneumonia and connected to the cluster of acute respiratory illness cases from Wuhan. The virus is transmitted from human to human via droplets coughed or exhaled by infected persons and by touching droplet-contaminated surfaces or objects and then touching the eyes, nose, or mouth. Population groups that have been more frequently reported as having severe disease and a higher mortality rate include people aged over 60 years, males, people with underlying conditions such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease, and cancer. Current estimates suggest a median incubation period of five to six days for COVID-19, with a range of one to 14 days. Disease-specific pharmaceuticals and vaccines are still under research and development. The therapeutic use of convalescent plasma donated by patients recovered from COVID-19 might play a role in the efforts to find a possible treatment for COVID-19. Keywords: Coronavirus, COVID-19, WHO, SARS-Cov-2, Zoonotic.


2020 ◽  
Author(s):  
Claudia Fortuna ◽  
Fabrizio Montarsi ◽  
Francesco Severini ◽  
Giulia Marsili ◽  
Luciano Toma ◽  
...  

Abstract BackgroundOn March 11 2020, the World Health Organization (WHO) declared COVID-19 outbreak a pandemic. As the mosquito season progressed, the understandable concern that such insects could transmit the virus began to spread. In response to this request, the vector competence for SARS-CoV-2 of Culex pipiens and Aedes albopictus, the two most common species of vector mosquitoes in Europe, was investigated. Due to the peculiar feeding behaviour, the role of Aedes albopictus in a potential mechanical transmission of the virus was also evaluated. MethodsFor the vector competence study, mosquitoes were allowed to take up an infectious blood meal. Mosquitoes were collected and analysed at 0, 3, 7 and 10 days post-feeding. For the mechanical transmission test Ae. albopictus females were allowed to feed for a short time on a feeder containing infectious blood and then on a feeder containing virus-free blood. Mosquitoes and blood were tested for viral presence.ResultsCx. pipiens and Ae. albopictus tested resulted not competent for SARS-CoV-2 and Ae. albopictus was unable to mechanically transmit the virus. ConclusionsThis study shows that the most common species of vector mosquitoes in Europe don’t transmit SARS-CoV-2 and, for the first time, that Ae. albopictus is unable to mechanically transmit the virus by feeding from a positive host to a healthy host.


Author(s):  
O.V. Bulgakova ◽  
◽  
G.A. Toksabayeva ◽  
A.A. Aripova ◽  
A.Zh. Kausbekova ◽  
...  

Mitochondria are unique cell organoids that have their own mitochondrial DNA. They are involved in the regulation of many processes, such as cell survival, apoptosis, and cellular metabolism. It has long been known that mitochondria play a leading role in the mechanism of malignant transformation in the development of many neoplasms. Radon is a radioactive inert gas, is recognized as a carcinogen and, according to the World Health Organization, it is the second cause of lung cancer after smoking. Radon is found in soil, water and air in various concentrations. Radon migrates from the soil and rocks into the surrounding air, as a result of which it accumulates in poorly ventilated or closed rooms. Such areas represent the primary environment in which people are exposed to radioactive radon radiation. Radon penetrates through cracks in the Earth's crust and accumulates in the lower layers of the atmosphere. An increase in the concentration of radon in the air is observed in regions rich in uranium deposits, as well as near uranium mines. However, at the moment, the mechanisms of malignant transformation induced by radon are still not completely clear. In this review, we consider for the first time the most modern understanding of the role of mitochondria in the molecular and cellular effects of ionizing radiation, including radon. This kind of knowledge can be of great importance for improving the antitumor effectiveness of radiation therapy, as well as for reducing damage to healthy cells exposed to ionizing radiation and protecting the population living in an area potentially dangerous for radon manifestations.


2020 ◽  
Vol 54 (2) ◽  
pp. 72-73
Author(s):  
Ernest Kenu ◽  
Joseph Frimpong ◽  
Kwadwo Koram

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China. The disease was christened COVID-19 and the pathogen (an RNA virus) identified as SARS-Coronavirus-2 (SARS-CoV-2).1,2 The virus is primarily spread through contact with small droplets produced from coughing, sneezing, or talking by an infected person. While a substantial proportion of infected individuals may remain asymptomatic, the most common symptoms in clinical cases include, fever, cough, acute respiratory distress, fatigue, and failure to resolve over 3 to 5 days of antibiotic treatment. Complications may include pneumonia and acute respiratory distress syndrome.3 Over five million confirmed cases of COVID-19 has been recorded globally with more than 300,000 deaths as at 25th May 2020. The United States of America has recorded the highest number of cases with more than 1.5 million and over 100,000 deaths.4 In Africa, more than 90,0000 cases have been reported with about 3,000 deaths. South Africa has recorded the highest number of cases with 23,615 cases and 481 deaths. Ghana confirmed its first cases of COVID-19 on 12th March 2020 and had as at 25 May 2020 recorded over 7,000 cases with 34 deaths.5  


2020 ◽  
Vol 3 (2) ◽  
pp. 243-263
Author(s):  
Adrita Banerjee ◽  
Aindrila Chattopadhyay ◽  
Debasish Bandyopadhyay

Diabetes mellitus, one of the crucial epidemics of this country has snatched the sleep of mankind with a steep slope of 108 million in 1980 to more than 460 million in today’s world. The global statistics based on numerological information from World Health Organization (WHO) proposed alarmingly about 642 million affected individuals by 2040. Type 1 diabetes is due to damaged pancreatic β-cells while type 2 diabetes is a result of insulin insensitivity associated with hyperglycaemia. Hyperglycaemia is a principal symptom of diabetes. As a result, the circulatory erythrocytes [red blood cells (RBCs)] become the first and most vulnerable victims to confront such a stressful environment. The RBCs possess many components including haemoglobin, membrane proteins and lipids. They prefer to interact with glucose and form glycated haemoglobin and membrane phospholipid asymmetry which alters RBC adherence. These alterations trigger intracellular reactive oxygen species (ROS) formation and oxidative damage in diabetic erythrocytes. Melatonin, an indoleamine, ameliorates oxidative stress in various tissues and has the capacity of shielding erythrocytes from deleterious stress. A crucial relationship between melatonin and insulin indicates their interplay in occurrence of diabetes. Biorhythm entrained and receptor mediated action of melatonin on pancreatic β-cells in the context of hyperglycaemia are discussed for the first time in the review. Since melatonin protects against erythrocytes, as well as beneficial to diabetes, it is worthy to address proficiency of this indoleamine to the diabetic erythrocytes. In summary, this review has discussed the fostering role of melatonin in hyperglycaemia and encouraged further investigation related to the molecular pathways of melatonin on glucose metabolism. 


Author(s):  
JOSÉ GUSTAVO PARREIRA ◽  
TERCIO DE CAMPOS ◽  
PEDRO DE SOUZA LUCARELLI ANTUNES ◽  
JACQUELINE ARANTES GIANNINNI PERLINGEIRO ◽  
JOSE CESAR ASSEF

ABSTRACT In December 2019, in Wuhan, China, the first cases of what would be known as COVID-19, a disease caused by an RNA virus called SARS-CoV-2, were described. Its spread was rapid and wide, leading the World Health Organization to declare a pandemic in March 2020. The disease has distinct clinical presentations, from asymptomatic to critical cases, with high lethality. Parallel to this, patients with non-traumatic surgical emergencies, such as acute appendicitis and cholecystitis, continue to be treated at the emergency services. In this regard, there were several doubts on how to approach these cases, among them: how to quickly identify the patient with COVID-19, what is the impact of the abdominal surgical disease and its treatment on the evolution of patients with COVID-19, in addition to the discussion about the role of the non-operative treatment for abdominal disease under these circumstances. In this review, we discuss these problems based on the available evidence.


Author(s):  
Lara Bittmann

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.


Author(s):  
Namita Misra

: Corona virus spreads from one to other person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. Covid-19 infected human symptoms are like any pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. First notified in china dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures everyone should follow the World Health Organization advice guidelines on the management of humans infected with known or suspected infection with SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same are under progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.


2020 ◽  
Vol 63 (4) ◽  
pp. 7-18 ◽  
Author(s):  
Anamary Súarez Reyes ◽  
Carlos Agustín Villegas Valverde

Characteristics and Specialization of the Immune Response in COVID-19 Abstract The outbreak of coronavirus pneumonia in Wuhan, China, became a pandemic on March 11, 2020. It has caused almost 4 million confirmed cases worldwide, with more than 270,000 deaths. Coronavirus is an enveloped RNA virus of the β-coronavirus genus distributed in birds, humans, and other mammals. The World Health Organization has named the new disease COVID-19. The scientific community is look http://doi.org/10.22201/fm.24484865e.2020.63.4.02 8 8 Revista de la Facultad de Medicina de la UNAM | ing for evidence that can lead to a better understanding of the infection and the immune response (IR), prognostic and therapeutic predictors, effective treatments and vaccines. The objective of this review was to compile updated scientific evidence of the IR to COVID-19, in order to guide professionals with solutions that have a clinical impact. The most important elements involve innate immunity with failures in the interferon system in the early stages of the infection and a sustained increase in proinflammatory interleukins. This can end in a potentially fatal cytokine storm. The infiltration of neutrophils and macrophages at the alveolar level, accompanied by neutrophilia, is very characteristic. Lymphopenia is evident at the adaptive immunity level, that, depending on the degree, can indicate the severity of the disease. Understanding the temporal sequence of the IR is crucial for choosing the appropriate and effective therapies, especially when selecting which type of anti-inflammatory drugs can be used and the frequency of the dosage. Due to the fact that it is difficult to determine when they will be clearly beneficial, not harmful to the IR and not too late, due to the irreversibility of the process. Key words: COVID-19; coronavirus; immune response


2021 ◽  
Vol 29 (Supplement_1) ◽  
pp. i45-i46
Author(s):  
A Peletidi ◽  
R Kayyali

Abstract Introduction Obesity is one of the main cardiovascular disease (CVD) risk factors.(1) In primary care, pharmacists are in a unique position to offer weight management (WM) interventions. Greece is the European country with the highest number of pharmacies (84.06 pharmacies per 100,000 citizens).(2) The UK was chosen as a reference country, because of the structured public health services offered, the local knowledge and because it was considered to be the closest country to Greece geographically, unlike Australia and Canada, where there is also evidence confirming the potential role of pharmacists in WM. Aim To design and evaluate a 10-week WM programme offered by trained pharmacists in Patras. Methods This WM programme was a step ahead of other interventions worldwide as apart from the usual measuring parameters (weight, body mass index, waist circumference, blood pressure (BP)) it also offered an AUDIT-C and Mediterranean diet score tests. Results In total,117 individuals participated. Of those, 97.4% (n=114), achieved the programme’s aim, losing at least 5% of their initial weight. The mean % of total weight loss (10th week) was 8.97% (SD2.65), and the t-test showed statistically significant results (P<0.001; 95% CI [8.48, 9.45]). The programme also helped participants to reduce their waist-to-height ratio, an early indicator of the CVD risk in both male (P=0.004) and female (P<0.001) participants. Additionally, it improved participants’ BP, AUDIT-C score and physical activity levels significantly (P<0.001). Conclusion The research is the first systematic effort in Greece to initiate and explore the potential role of pharmacists in public health. The successful results of this WM programme constitute a first step towards the structured incorporation of pharmacists in public’s health promotion. It proposed a model for effectively delivering public health services in Greece. This study adds to the evidence in relation to pharmacists’ CVD role in public health with outcomes that superseded other pharmacy-led WM programmes. It also provides the first evidence that Greek pharmacists have the potential to play an important role within primary healthcare and that after training they are able to provide public health services for both the public’s benefit and their clinical role enhancement. This primary evidence should support the Panhellenic Pharmaceutical Association, to “fight” for their rights for an active role in primary care. In terms of limitations, it must be noted that the participants’ collected data were recorded by pharmacists, and the analysis therefore depended on the accuracy of the recorded data, in particular on the measurements or calculations obtained. Although the sample size was achieved, it can be argued that it is small for the generalisation of findings across Greece. Therefore, the WM programme should be offered in other Greek cities to identify if similar results can be replicated, so as to consolidate the contribution of pharmacists in promoting public health. Additionally, the study was limited as it did not include a control group. Despite the limitations, our findings provide a model for a pharmacy-led public health programme revolving around WM that can be used as a model for services in the future. References 1. Mendis S, Puska P, Norrving B, World Health Organization., World Heart Federation., World Stroke Organization. Global atlas on cardiovascular disease prevention and control [Internet]. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011 [cited 2018 Jun 26]. 155 p. Available from: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/ 2. Pharmaceutical Group of the European Union. Pharmacy with you throughout life:PGEU Annual Report [Internet]. 2015. Available from: https://www.pgeu.eu/en/library/530:annual-report-2015.html


Sign in / Sign up

Export Citation Format

Share Document